York-based life sciences business OptiBiotix Health has hailed a “period of exciting progress” in its half-year results.
The listed company reported revenue of £744,821 for the six months to 30 June 2020, up from £148,818 in the same period of 2019.
York-based life sciences business OptiBiotix Health has hailed a “period of exciting progress” in its half-year results.
The listed company reported revenue of £744,821 for the six months to 30 June 2020, up from £148,818 in the same period of 2019.
Pre-tax losses also reduced to £614,909 from £1.26m the year before,
During the period, OptiBiotix launched its branded SlimBiome product range with Holland & Barrett.
Stephen O’Hara, chief executive of OptiBiotix, said: “This has been another period of exciting progress for OptiBiotix with a 400 per cent increase in sales and a large reduction in costs compared to the same period last year. Our divisions are now making strong progress towards profitability with more agreements generating revenues, existing partners increasing sales, and more retail partners launching successful new products.
“Our products are now being commercialised with large retail and pharmaceutical partners boosting consumer awareness and confidence in our brands with OptiBiotix now being identified as a key player in the microbiome space within industry.”
For the full story, please visit the Insider Media website.
